Clinical trials: Cardiac Disorder
- Condition Cardiac Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Coronary Artery Disease
A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers
In this study, the relative bioavailability of different formulations of AZD5718 will be determined in order to compare it with the formulation used in a previous Phase 2a study and confirm appropriate drug exposure.
- Trial name
- NCT03420092
- Testing
- Form 1 of AZD5718 tablets, Form 2 of AZD5718 tablets, Form 3 of AZD5718 tablets
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease
A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease
Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD subjects both male and female between the ages of 50-85.
- Trial name
- NCT00413647
- Testing
- CardioPET
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Long QT Syndrome
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
- Trial name
- NCT02365532
- Testing
- GS-6615, Dofetilide
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Patent Foramen Ovale
Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism
The primary objective of this study is to demonstrate the safety of the PFX Closure System when utilized for patients with patent foramen ovale (PFO) suffering from cryptogenic stroke, transient ischemic attacks or paradoxical…
- Trial name
- NCT00196027
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cierra
Atrial Fibrillation
The Validation of the FibriCheck Application for the Detection of Atrial Fibrillation
Optical sensing technologies have the potential to enable long-term heart rhythm monitoring. The medically certified and clinically validated FibriCheck technology has proven its value for spot-check measurements to detect AF.
- Trial name
- FLASH-AF (NCT03620656)
- Testing
- FibriCheck
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Qompium NV
Heart Failure
Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Primary Trial objectives: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose…
- Trial name
- COR-1-01 (NCT01043146)
- Testing
- COR-1
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Corimmun GmbH
Arrhythmias, Cardiac
12 Lead ECG Database
The purpose of this investigation is to collect a database of simultaneous electrocardiogram (ECG) recordings from the SANSA device and a reference 12-lead ECG recording device.
- Trial name
- NCT06513637
- Testing
- 12-Lead ECG and home sleep study (HST) diagnostics
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Huxley Medical, Inc.
Healthy Volunteers, Heart Failure
A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants
This study is being done to understand how much of the medicine (CDR132L) enters the bloodstream after injection under the skin compared to injection into a vein in healthy people.
- Trial name
- NCT07656454
- Testing
- CDR132L (i.v.), CDR132L (s.c.)
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Coronary Artery Disease
A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.
- Trial name
- NCT00733460
- Testing
- BFPET
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Persistent Atrial Fibrillation
A Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.
This prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation.
- Trial name
- NCT07590661
- Testing
- superior vena cava isolation, Abnormal left atrial substrate
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hangzhou Dinova EP Technology Co., Ltd
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Myocardial Infarction
A Study of NP-011 in Healthy Volunteers
This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.
- Trial name
- NCT05387499
- Testing
- NP-011 (Single Ascending Dose Phase), NP-011 (Multiple Ascending Dose Phase)
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Nexel Co., Ltd.
Anemia, Diabetes
A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
1. Aim: The aim of the clinical trial is to study the accuracy of the TensorTip device compared with registered (FDA-approved) invasive and non-invasive devices. 2.
- Conditions
- Anemia, Diabetes, Heart Disease, High Blood Pressure
- Trial name
- NCT01196533
- Testing
- Non invasive peripheral blood monitoring
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Cnoga Medical Ltd.
HIV Infections
Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin
This study will aim to evaluate the effect of therapeutic and supratherapeutic oral doses of GSK3640254 on cardiac conduction compared to placebo and a single oral dose of Moxifloxacin in healthy adult participants.
- Trial name
- NCT04563845
- Testing
- GSK3640254, Moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Myocardial Infarction
Statins and Risk of Myocardial Infarction in Real Life in France
The main objective of this case-referent study is to assess the impact of statins usage on the risk of having a first myocardial infarction (MI) in a real life situation in France
- Trial name
- NCT00679575
- Where
- 56 sites in France
- Volunteers
- 13,171 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myocardial Infarction, Ischemia
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps.
- Conditions
- Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases
- Trial name
- STLEUISII (NCT06271577)
- Testing
- AliveCor 12-lead ECG
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- AliveCor
Acute Myocardial Injuries
Mason Heart Study With MCG
Heart disease is the number one cause of death in the United States, with over 650,000 deaths in 2019 alone. Many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood…
- Trial name
- MHS-MCG (NCT04732975)
- Testing
- CardioFlux
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Genetesis Inc.
Atherosclerosis
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days.
- Trial name
- NCT00411073
- Testing
- Darapladib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension, Chronic Stable Angina
Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Amlodipine Besylate tablets, 10 mg, to Norvasc® Tablets, 10 mg (Pfizer) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period…
- Conditions
- Hypertension, Chronic Stable Angina, Vasospastic Angina
- Trial name
- NCT00602017
- Testing
- Amlodipine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Drug Safety, Heart; Disease, Activity
Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects
Study Phase: Phase 1 Primary Objective: To evaluate the safety and tolerability of single ascending oral doses of CARD-024 in healthy subjects Secondary Objectives: To evaluate the pharmacokinetic (PK) profile of CARD-024…
- Trial name
- CARD-024 (NCT01757860)
- Testing
- CARD-024, Drug Carrier
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Cardiavent Inc.